These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 32955827

  • 1. Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.
    Cangini D, Silimbani P, Cafaro A, Giannini MB, Masini C, Ghelli Luserna Di Rorà A, Simonetti G, Martinelli G, Cerchione C.
    Minerva Med; 2020 Oct; 111(5):467-477. PubMed ID: 32955827
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.
    Jen WY, Konopleva M, Pemmaraju N.
    Cancer; 2024 Jul 01; 130(13):2260-2271. PubMed ID: 38620053
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Tagraxofusp in myeloid malignancies.
    Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Neri A, Imovilli A, Morabito F, Vigna E, Gentile M.
    Hematol Oncol; 2024 Jan 01; 42(1):e3234. PubMed ID: 37846131
    [Abstract] [Full Text] [Related]

  • 16. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Jain A, Sweet K.
    J Natl Compr Canc Netw; 2023 May 01; 21(5):515-521. PubMed ID: 37156483
    [Abstract] [Full Text] [Related]

  • 17. Targeting CD123 in BPDCN: an emerging field.
    DiPippo AJ, Wilson NR, Pemmaraju N.
    Expert Rev Hematol; 2021 Nov 01; 14(11):993-1004. PubMed ID: 34607517
    [Abstract] [Full Text] [Related]

  • 18. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.
    Togami K, Pastika T, Stephansky J, Ghandi M, Christie AL, Jones KL, Johnson CA, Lindsay RW, Brooks CL, Letai A, Craig JW, Pozdnyakova O, Weinstock DM, Montero J, Aster JC, Johannessen CM, Lane AA.
    J Clin Invest; 2019 Nov 01; 129(11):5005-5019. PubMed ID: 31437130
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.